^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD22 positive

    i
    Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
    Entrez ID:
    933
    Related biomarkers:
    Expression
    1d
    A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P4, N=44, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    21d
    Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma. (PubMed, Front Immunol)
    The patient achieved short-term remission with bortezomib in combination with etoposide, dexamethasone, cyclophosphamide, and doxorubicin as first-line therapy. After disease progression, the patient received daratumumab combined with GemOx as second-line treatment but showed no response...The patient received CD19 and CD22 CAR-T therapies as the third-line treatment and achieved durable complete remission for more than one year with good tolerance. A patient with refractory PBL achieved durable complete remission after CD19 and CD22 CAR-T therapies, suggesting this treatment may be effective for patients with refractory or relapsing PBL.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Darzalex (daratumumab)
    2ms
    A CD22-Specific T-Cell Receptor Enables Effective Adoptive T-Cell Therapy for B-cell malignancies. (PubMed, Blood)
    Notably, in-vivo validation in a Nalm6 B-cell leukemia model confirmed the superior activity of CD22 TCR-T cells against CD22low cells compared to CD22 CAR-T cells. In conclusion, our findings provide strong preclinical evidence supporting CD22 TCR-based therapy as a potent treatment option for CD22low B-cell malignancies, including patients who relapsed following CD19 CAR-T therapy.
    Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CD22 (CD22 Molecule)
    |
    CD22 positive
    6ms
    To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Hebei Senlang Biotechnology Inc., Ltd. | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD20 positive • CD19 positive • CD22 positive
    6ms
    IRB-50836: Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
    P1, N=52, Completed, Stanford University | Active, not recruiting --> Completed | Trial completion date: Dec 2037 --> Mar 2025
    Trial completion • Trial completion date
    |
    CD22 positive • CD20 negative
    |
    cyclophosphamide • fludarabine IV • firicabtagene autoleucel (CRG-022)
    6ms
    Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin)
    6ms
    Plasma Cell Leukemia With Spindle-Cell Morphology and CD22 Positivity on Flow Cytometry. (PubMed, Cureus)
    Additionally, CD22 positivity suggests a unique immunophenotypic profile, potentially representing an intermediate stage between immunoblasts and mature plasma cells. This report documents the first case of CD22-positive PCL with spindle cell morphology.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
    |
    CD20 positive • CD22 positive
    7ms
    Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov)
    P2, N=14, Completed, Beijing Boren Hospital | Recruiting --> Completed | N=100 --> 14
    Trial completion • Enrollment change • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    cyclophosphamide • fludarabine IV • Anti-CD22 CAR-T Cells
    8ms
    CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy. (PubMed, J Immunother Cancer)
    The favorable safety profile and high remission rates in exceedingly refractory B-ALL support the continued development of CART22-65s but also highlight the need to use the product in combination with HCT or other novel strategies.
    Journal
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Besponsa (inotuzumab ozogamicin) • CART22
    8ms
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
    10ms
    A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    11ms
    Venetoclax Plus Inotuzumab for B-ALL (clinicaltrials.gov)
    P1, N=26, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)